#USA #San Diego #Neurocrine Biosciences #CNS Forum #NBIX

Neurocrine Biosciences Participation at Stifel's 2026 Virtual CNS Forum

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a frontrunner in the biopharmaceutical landscape, is gearing up to showcase its advancements at the Stifel 2026 Virtual CNS Forum. Scheduled for March 17, 2026, at 4:30 PM EST, this event will provide a platform to share essential insights from their management team.

The live streaming of the presentation will be easily accessible through Neurocrine's investor relations page at neurocrine.com. For those unable to attend live, a recorded version will be available shortly after the event and will remain accessible for a month, ensuring a wider audience can engage with their presentation.

Neurocrine Biosciences has a clear mission to alleviate suffering for individuals with significant healthcare needs. Their dedication extends to discovering, developing, and commercializing groundbreaking treatments for a range of conditions that often go under-recognized, including neurological, psychiatric, endocrine, and immunological disorders.

Their portfolio is not only diverse but also includes FDA-approved therapies targeting various challenges faced by patients. Alongside existing treatments for tardive dyskinesia and Huntington's disease chorea, Neurocrine is advancing towards new horizons with multiple compounds currently in mid- to late-phase clinical development. This positions them as pioneers in their quest to tackle complex medical issues.

For three decades, the company has drawn on its comprehensive understanding of neuroscience and the intricate connections between brain and body systems. They persist in their ambitions to create effective treatments aimed at alleviating the burdens of debilitating diseases. Their approach, branded as 'brave science', reflects their commitment to innovative therapeutic solutions.

The significance of Neurocrine's participation in the Stifel 2026 Forum cannot be overstated. As stakeholders in the biopharmaceutical and healthcare industry, the forum will enable insights into the latest research developments, clinical findings, and potential breakthroughs that may shape the future of treatment methodologies. The event not only reinforces their role as leaders in innovative healthcare but also highlights the importance of ongoing dialogue in scientific communities.

Beyond their immediate contributions, Neurocrine is also focused on leveraging collaborative efforts, such as their partnerships with other industry leaders like AbbVie, as they work towards delivering comprehensive solutions for various health challenges including endometriosis and uterine fibroids.

In summary, the upcoming Stifel 2026 Virtual CNS Forum represents a pivotal moment for Neurocrine Biosciences. It is an opportunity to unveil their extensive work and share essential updates about the future of neurological treatment. Engaging with fellow innovators, healthcare professionals, and investors will undoubtedly carve pathways towards significant advancements in the medical field. With a proactive approach and a sustained focus on innovation, Neurocrine continues to exemplify what it means to push boundaries in biopharmaceutical development. Attendees can anticipate an enriching experience packed with vital insights that could potentially influence treatment paradigms.